- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Theses and Dissertations /
- Pharmacogenomic study of vincristine-induced peripheral...
Open Collections
UBC Theses and Dissertations
UBC Theses and Dissertations
Pharmacogenomic study of vincristine-induced peripheral neuropathy in patients with pediatric cancers Mufti, Kheireddin
Abstract
Vincristine is a cornerstone chemotherapeutic agent widely used for the treatment of various pediatric cancers. However, its clinical utility is often compromised by the occurrence of vincristine-induced peripheral neuropathy, which significantly impacts quality of life due to pain and disability, and may require dose reduction, treatment delays or discontinuation that increases the risk of relapse. While several studies have identified genetic factors that are associated with vincristine peripheral neuropathy risk, these variants do not fully explain the variability in the risk of this reaction, and the clinical relevance of many variants remains unclear. As result, there are currently no established predictors of peripheral neuropathy risk prior to the start of vincristine treatment. This dissertation aims therefore to identify, and validate, novel genomic markers of vincristine-induced neuropathy in pediatric cancer patients. A systematic review of existing genetic associations with vincristine-induced peripheral neuropathy was performed and demonstrated that variations in genes implicated in vincristine pharmacokinetics, pharmacodynamics, and neuropathy-related pathways are associated with vincristine-induced peripheral neuropathy susceptibility. Among these, the CEP72 rs924607 gene variant emerged as the most robustly supported variant influencing neuropathy risk. I subsequently conducted a genome-wide association study uncovering 13 novel genomic variants significantly associated with vincristine neuropathy risk or protection. Of these, I successfully validated two variants an independent replication cohort. Notably, patients carrying protective variants in both NRG3 and ACTN1 genes exhibited a substantial reduction in neuropathy incidence over time (HR=0.36, 95% CI: 0.124–0.602; p
Item Metadata
Title |
Pharmacogenomic study of vincristine-induced peripheral neuropathy in patients with pediatric cancers
|
Creator | |
Supervisor | |
Publisher |
University of British Columbia
|
Date Issued |
2025
|
Description |
Vincristine is a cornerstone chemotherapeutic agent widely used for the treatment of various pediatric cancers. However, its clinical utility is often compromised by the occurrence of vincristine-induced peripheral neuropathy, which significantly impacts quality of life due to pain and disability, and may require dose reduction, treatment delays or discontinuation that increases the risk of relapse. While several studies have identified genetic factors that are associated with vincristine peripheral neuropathy risk, these variants do not fully explain the variability in the risk of this reaction, and the clinical relevance of many variants remains unclear. As result, there are currently no established predictors of peripheral neuropathy risk prior to the start of vincristine treatment. This dissertation aims therefore to identify, and validate, novel genomic markers of vincristine-induced neuropathy in pediatric cancer patients.
A systematic review of existing genetic associations with vincristine-induced peripheral neuropathy was performed and demonstrated that variations in genes implicated in vincristine pharmacokinetics, pharmacodynamics, and neuropathy-related pathways are associated with vincristine-induced peripheral neuropathy susceptibility. Among these, the CEP72 rs924607 gene variant emerged as the most robustly supported variant influencing neuropathy risk. I subsequently conducted a genome-wide association study uncovering 13 novel genomic variants significantly associated with vincristine neuropathy risk or protection. Of these, I successfully validated two variants an independent replication cohort. Notably, patients carrying protective variants in both NRG3 and ACTN1 genes exhibited a substantial reduction in neuropathy incidence over time (HR=0.36, 95% CI: 0.124–0.602; p
|
Genre | |
Type | |
Language |
eng
|
Date Available |
2025-05-20
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution-NonCommercial-NoDerivatives 4.0 International
|
DOI |
10.14288/1.0448919
|
URI | |
Degree (Theses) | |
Program (Theses) | |
Affiliation | |
Degree Grantor |
University of British Columbia
|
Graduation Date |
2025-11
|
Campus | |
Scholarly Level |
Graduate
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International